Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26639714 | 0.83 | HTR2A (0.46) | HTR2AHRH1CCKBR | |
| SCHEMBL30622634 | 0.83 | HTR2A (0.46) | HTR2AHRH1CCKBR | |
| SCHEMBL14048618 | 0.83 | HTR2A (0.46) | HTR2AHRH1CCKBR | |
| SCHEMBL26639717 | 0.83 | HTR2A (0.46) | HTR2AHRH1CCKBR | |
| SCHEMBL1030313 | 0.83 | SLC6A4 (0.40) | CCKBRSLC6A4 | |
| SCHEMBL8649621 | 0.80 | HTR2A (0.49) | HTR2AHRH1CCKBR | |
| SCHEMBL12141050 | 0.79 | CCKBR (0.42) | HTR2ACCKBR | |
| SCHEMBL1118519 | 0.79 | CCKBR (0.42) | HTR2ACCKBR | |
| SCHEMBL12013752 | 0.79 | CCKBR (0.42) | HTR2ACCKBR | |
| Hydrochloric Acid SCHEMBL29960215 | 0.79 | BCHE (0.42) | HTR2AHRH1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102548970-B | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SAI NUOFEI (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-8993565-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993565-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993565-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-10-09 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| CN-102548970-A | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | HTR2A 1412/4885HRH1 590/4885CCKBR 1541/4885 |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | HTR2A 1412/4885HRH1 590/4885CCKBR 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.